Second Open Label Extension to Bridging Study CTBM100C2303

Clinical Trial Summary

This was an open-label, single arm (uncontrolled) study in participants suffering from cystic fibrosis, who have completed their study participation in CTBM100C2303 and extension study one CTBM100C2303E1 (all visits), who were proven infected with Pseudomonas aeruginosa at enrollment into CTBM100C2303.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04335383` - Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Not yet recruiting	`NCT06035055` - Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis	Phase 4
Completed	`NCT00774072` - Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization	Phase 2
Completed	`NCT00515229` - Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo	Phase 2
Terminated	`NCT00333385` - Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis	Phase 4
Recruiting	`NCT03638830` - Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa	Phase 2
Enrolling by invitation	`NCT05880069` - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Completed	`NCT00633191` - Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis	Phase 1/Phase 2
Completed	`NCT00712166` - Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa	Phase 3
Recruiting	`NCT04171817` - Animal-Assisted Visitation Program Chlorhexidine Trial	Phase 4
Completed	`NCT02696902` - Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects	Phase 2
Completed	`NCT01319253` - A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies	N/A
Recruiting	`NCT05282082` - Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Recruiting	`NCT04803695` - Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease
Not yet recruiting	`NCT05632315` - PMT for MDRO Decolonization	Phase 2
Completed	`NCT01055847` - Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection	Phase 2
Completed	`NCT01745796` - Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)
Recruiting	`NCT04673175` - Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation	Phase 1/Phase 2
Terminated	`NCT05210387` - Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections	N/A
Recruiting	`NCT05616221` - Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection	Phase 2

NCT number	NCT01069705
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	February 12, 2010
Completion date	March 19, 2012

Second Open Label Extension to Bridging Study CTBM100C2303

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms